Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.
By A. Sabchareon, D. Wallace, C. Sirivichayakul, K. Limkittikul, P. Chanthavanich, S. Suvannadabba, Vithaya Jiwariyavej, Wut Dulyachai, K. Pengsaa, T. Wartel and 6 more. The Lancet, 2012
831 citations recorded by the source corpus.
Subfields: Endocrinology, Infectious Diseases, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/f32ade2d409d1e0e5bc772db8687ad0651eebd6e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells (2013, result): “The protective role of T cells in humans was supported by this study and reverberates with renewed urgency and newsworthiness in light of a recent phase 2b proof-of-concept efficacy vaccine trial (40) that showed only 30% overall efficacy, demonstrating partial (60–80%) protection toward 3 of 4 DENV”